A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibators and lofepramine

Health Technology Assessment

Volumn 9, Issue 16, 2005, Pages

  Peveler, Robert ^a   Kendrick, Tony ^a   Buxton, M ^a   Longworth, L ^a   Baldwin, David ^a   Moore, M ^a   Chatwin, J ^a   Goddard, J ^a   Thornett, A ^a   Smith, H ^a   Campbell, M ^a   Thompson, Chris ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DOSULEPIN; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG PREFERENCE; DRUG WITHDRAWAL; FOLLOW UP; GENERAL PRACTITIONER; HEALTH SERVICE; HEALTH STATUS; HUMAN; INTERVIEW; LINEAR REGRESSION ANALYSIS; MEDICAL DECISION MAKING; MEDICAL RECORD; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; RURAL AREA; SOCIAL ASPECT; UNITED KINGDOM; URBAN AREA;

EID: 21044457536     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Murray CJL, Lopez AD. The global burden of disease. Cambridge, MA: Harvard University Press; 1996.
2. Chisholm D, Diehr P, Knapp M, Patrick D, Treglia M, Simon G. Depression status, medical comorbidity and resource costs: evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry 2003;183:121-31.
3. Goldberg DP, Huxley P. Common mental disorders: a bio-social model. London: Routledge; 1992.
4. Department of Health. Prescribing figures. London: Department of Health; 2002.
5. Prescription Pricing Authority. Prescribing of antidepressants in England (April-June 2001). 2001. Available from http://www.ppa.nhs.uk/news/pact-11. Accessed July 2003.
6. Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technol Assess 2001;5(35).
7. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992; 305:1198-202.
8. Peveler R, Kendrick T. Treatment delivery and guidelines in primary care. Br Med Bull 2001; 57:193-206.
9. Anderson IM, Nutt DJ. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14:3-20.
10. Gilbody S, Whitty P, NHS Centre for Reviews and Dissemination, University of York. Improving the recognition and management of depression in primary care. Effective Health Care 2002;7:1-12.
11. Meltzer M, Gill B, Petticrew M. The prevalence of psychiatric morbidity among adults aged 16-64, living in private households, in Great Britain. London: Office of Population Censuses and Surveys; 1995.
12. Bebbington P, Hurry J, Tennant C, Sturt E, Wing JK. Epidemiology of mental disorders in Camberwell. Psychol Med 1981; 11:561-79.
13. Wells K, Stewart A, Hayes RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depression patients. Results from the Medical Outcomes Study. JAMA 1989; 262:914-19.
14. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days and days lost from work in a prospective epidemiologic survey. JAMA 1990;264:2524-8.
15. Patel A, Knapp M. Costs of mental illness in England. Mental Health Research Review 1998; 5:4-10.
16. Freeling P, Rao BM, Paykel ES, Sireling LI, Burton RH. Unrecognised depression in general practice. BMJ 1985; 290:1880-3.
17. Blacker CVR, Clare AW. The prevalence and treatment of depression in general practice. Psychopharmacology 1988; 95(Suppl):S14-17.
18. Woods SW, Rizzo JA. Cost effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997;170:257-63.
19. Coyne JC, Fechner-Bates S, Schwenk TL. Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry 1994;16:267-76.
20. Sireling LI, Paykel ES, Freeling P, Rao BM, Patel SP. Depression in general practice: case thresholds and diagnosis. Br J Psychiatry 1985;147:113-19.
21. Mann A, Jenkins R, Belsey E. The twelve-month outcome of patients with neurotic illness in general practice. Psychol Med 1981;11:535-50.
22. Wright AF, Anderson AJB. Newly identified psychiatric illness in one general practice: 12 month outcome and the influence of patients' personality. Br J Gen Pract 1995;45:83-7.
23. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. Selective serotonin reuptake inhibitors: a meta analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9:47-53.
24. Lloyd KR, Jenkins R, Mann A. Long term outcome of patients with neurotic illness in general practice. BMJ 1996; 313:26-8.
25. van Weel-Baumgarten E, van den Bosch W, van den Hoogen H, Zitman H. Ten year follow-up of depression after diagnosis in general practice. Br J Gen Pract 1998;48:1643-6.
26. Bridges K, Goldberg DP. Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosom Res 1985; 29:563-9.
27. de Lima MS, Hotopf M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychol Med 1999;29:1273-89.
28. Hollyman JA, Freeling P, Paykel ES, Bhat A, Sedgwick P. Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. Journal of the Royal College of General Practitioners 1988;38:393-7.
29. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-78.
30. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-7.
31. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta analysis and investigation of heterogeneity. Br J Psychiatry 1997;170:120-7.
32. Simon GE, Lin EH, Katon W. Outcomes of 'inadequate' antidepressant treatment. J Gen Intern Med 1995;10:663-70.
33. Revicki DA, Simon GE, Katon W, Heiligenstein J. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998; 47:446-52.
34. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta analysis. BMJ 1995;310:1433-8.
35. Furukawa TA, McGuire TA, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002;325:991-5.
36. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996; 168:164-8.
37. Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR. Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom. J Pychopharmacol 1999; 13:136-43.
38. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988;104:84-96.
39. Lin EH, Katon W, Vonkorff M, Russo JE, Simon GE, Bush TM, et al. Relapse of depression in primary care: rate and clinical predictors. Archives of Family Medicine 1998;7:443-9.
40. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression (Cochrane review). In: The Cochrane Libra ry, Issue 4. Chichester: John Wiley; 2004.
41. Loonen AJ, Peer PG, Zwanikken GJ. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharmaceutisch Weekblad - Scientific Edition 1991; 13:167-75.
42. Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull 2001;57:145-59.
43. Kendrick T, Stevens L, Bryant A, Goddard J, Stevens A, Raftery J, et al. Hampshire Depression Project: changes in the process of care and cost consequences. Br J Gen Pract 2001; 51:911-13.
44. Von Korff M, Goldberg D. Improving outcomes in depression. BMJ 2001;323:948-9.
45. Priest RG, Vize C, Roberts A, Roberts M, Tylee A. Lay people's attitude to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ 1996; 313:858-9.
46. Kendrick T. Why can't GPs follow guidelines on depression? BMJ 2000;320:200-1.
47. Kendrick T. Depression management clinics in general practice? Some aspects lend themselves to the mini-clinic approach. BMJ 2000;320:527-8.
48. Pande AC, Sayler ME. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 1993;8:243-5.
49. Gilbody S, Sheldon T, Song F, House A. Prescribing antidepressants in general practice. Costs should have been considered. BMJ 1997; 314:828-9.
50. Martin RM, Hilton SR, Kerry SM, Richards NM. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ 1997;314: 646-51.
51. Thompson C, Peveler R, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry 2000;157:338-43.
52. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricycylic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003;326:1014-17.
53. Scott J. Psychological treatments for depression: an update. Br J Psychiatry 1995;167:131-4.
54. Weissman MM, Markowitz JC. Interpersonal psychotherapy. Current status. Arch Gen Psychiatry 1994;51:599-606.
55. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995;310:441-5.
56. Gloaguen V, Cottraux J, Cucherat M, Blackburn IM. A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 1998;49:59-72.
57. Mynors-Wallis LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000;320:26-30.
58. Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V, et al. Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. BMJ 2000;321:1450-4.
59. Barrett JE, Williams JW, Oxman TE, Frank E, Katon W, Sullivan M, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001;50:405-12.
60. Williams JW, Barrett J, Oxman T, Frank E, Katon W, Sullivan M, et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in oider adults. JAMA 2000; 284:1519-26.
61. Harvey I, Nelson SJ, Lyons RA, Unwin C, Monaghan S, Peters TJ. A randomized controlled trial and economic evaluation of counselling in primary care. Br J Gen Pract 1998;48:1043-8.
62. Hemmings A. Counselling in primary care: a randomised controlled trial. Patient Education and Counselling 1997; 32:219-30.
63. Friedli L, King M, Lloyd M, Horder J. Randomised controlled assessment of non-directive psychotherapy versus routine general-practitioner care. Lancet 1997;350:1662-5.
64. Boot D, Gillies P, Fenelon J, Reubin R, Wilkins M, Gray P. Evaluation of the short-term impact of counselling in general practice. Patient Education and Counselling 1994;24:79-89.
65. Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression 1: Clinical effectiveness. BMJ 2000; 321:1383-8.
66. Simpson S, Corney R, Fitzgerald P, Beecham J. A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of psychodynamic counselling for general practice patients with chronic depression. Psychol Med 2003;33:229-39.
67. Bower P, Rowland N, Mellor Clark J, Heywood P, Godfrey C, Hardy R. Effectiveness and cost-effectiveness of counseling in primary care (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester. John Wiley; 2004.
68. Cuijpers P. Bibliotherapy in unipolar depression: a meta-analysis. J Behav Ther Exp Psychiatry 1997; 28:139-47.
69. Bower P, Richards D, Lovell K. The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: A systematic review. Br J Gen Pract 2001;51:838-45.
70. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997;58:47-58.
71. Nuijten M, Hadjadjeba L, Evans C, van den Berg J. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998;14:433-45.
72. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-73.
73. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994;5:249-64.
74. Doyle JJ, Casciano J, Arikian S, Tarride J, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16-31.
75. Stewart A. Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. British Journal of Medical Economics 1994; 7:67-79.
76. Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17:136-53.
77. Canadian Coordinating Office for Health Technology Assessment. A clinical and economic evaluation of selective serotonin reuptake inhibitors in major depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
78. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38:97-111.
79. Simon GE, von Korff M, Heiligenstein M, Revicki DA, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care - effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-902.
80. Hosak L, Tuma I, Hanus H, Straka L. Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study. Acta Med 2000;43:133-6.
81. Thompson C. Management of depression in real-life settings: knowledge gained from large-scale clinical trials. Int Clin Psychopharmacol 1994; 9(Suppl 3):21-5.
82. Simon GE, Heiligenstein JH, Revicki DA, Vonkorff M, Katon WJ, Ludman E, et al. Long-term outcomes of initial antidepressant drug choice in a 'real world' randomized trial. Archives Family Medicine 1999;8:319-25.
83. Bradley C. Designing medical and educational intervention studies. Diabetes Care 1993;16:509-18.
84. Fairhurst K, Dowrick C. Problems with recruitment in a randomised controlled trial of counselling in general practice: causes and implications. Journal of Health Services Research and Policy 1996;1:77-80.
85. Gotay CC. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med 1991;33:569-77.
86. Torgerson DJ, Klaber-Moffett J, Russell IT. Patient preferences in randomised trials: threat or opportunity? Journal of Health Services Research and Policy 1996;1:194-7.
87. Rucker G. A two-stage trial design for testing treatment, self-selection and treatment preference effects. Stat Med 1989; 8:477-85.
88. Wennberg JE, Barry MJ, Fowler FJ, Mulley A. Outcomes research, PORTS, and health care reform. Ann N Y Acad Sci 1993; 703:52-62.
89. Zelen M. A new design for randomised clinical trials. N Engl J Med 1979;300:1242-5.
90. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ 1989;299:313-15.
91. Silverman WA, Altman DG. Patients' preferences and randomised clinical trials. Lancet 1996; 347:171-4.
92. Olschewski M, Scheurlen H. Comprehensive cohort study: an alternative to randomised consent design in a breast preservation trial. Methods Inf Med 1985;24:131-4.
93. Katon W, Von korff M, Lin E, Walker E, Simon G, Robinson P, et al. Methodologic issues in randomised controlled trials of liaison psychiatry in primary care. Psychosom Med 1994; 56:97-103.
94. Lewis G, Pelosi AJ, Araya RC, Dunn G. Measuring psychiatric disorder in the community: the development of a standardised assessment for use by lay interviewers. Psychol Med 1992;22:465-86.
95. World Health Organisation. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: WHO; 1993.
96. Jenkins R, Meltzer H. The national survey of psychiatric morbidity in Great Britain. Soc Psychiatry Psychiatr Epidemiol 1995;30:1-4.
97. Lewis G. Assessing psychiatric disorder with a human interviewer or a computer. J Epidemiol Community Health 1994; 48:207-10.
98. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-70.
99. Brooks R. EQ-5D, the current state of play. Health Policy 1996;37:53-72.
100. EQ-5D Group. EQ-5D a new facility for the measurement of health related quality of life. Health Policy 1990; 16:199-208.
101. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997;35:1095-108.
102. Dolan P, Gudex C, Kind P, Williams A. The TTO method, results from a general population survey. Health Econ 1996; 5:141-54.
103. Ware J, Snow KK, Kosinski M, Gandek B. SF-36 health survey, manual and interpretation guide. Boston, MA: Health Institute, New England Medical Centre; 1993.
104. British Association of Psychopharmacology. Guidelines for Treating Depressive Illness with Antidepressants: A statement from the British Association for Psychopharmacology. J Psychopharmacol 1993;7:19-23.
105. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313:36-9.
106. Fairclough D. Design and analysis of quality of life studies in clinical trials. London: Chapman and Hall; 2002.
107. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 42nd ed. London: BMJ Books; 2001.
108. Netten A, Rees T, Harrison G. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2001.
109. Ratcliffe J, Ryan M, Tucker J. The costs of alternative types of routine antenatal care for low-risk women: shared care vs care by general practitioners and community midwives. Journal of Health Services Research and Policy 1996;1: 135-40.
110. Moffett JK, Torgerson D, Bell-Syer SB, Jackson D, Lliewlyn-Phillips H, Farrin A, et al. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs and preferences. BMJ 1999;319:279-83.
111. Brown JS, Smith RR, Cantor T, Chesover D, Yearsley R. General practitioners as providers of minor surgery - a success story? Br J Gen Pract 1997;47:205-10.
112. Manly BFJ. Randomisation, bootstrap and Monte Carlo methods in biology. 2nd ed. London: Chapman and Hall; 1997.
113. Pocock S, Assmann S, Enos L, Kasaten L. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21:2917-30.
114. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 45th ed. London: BMJ Books; 2003.
115. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84.
116. National Collaborating Centre for Mental Health. Depression: the management of depression in primary and secondarv care. Draft guidelines for consultation. London: National Institute for Clinical Excellence, Department of Health; 2003.
117. Thompson C, Kinmonth A-L, Stevens L, Peveler R, Stevens A, Ostler KJ, et al. Effects of clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial. Lancet 2000; 355:185-91.
118. Schwenk TL, Coyne JC, Fechner BS. Differences between detected and undetected patients in primary care and depressed psychiatric outpatients. Gen Hosp Psychiatry 1996; 18:407-15.
119. Sullivan SD, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996;154(Suppl):S84-95.
120. Sullivan SD, Liljas B, Buxton M, Lamm CJ, D'Byrne P, Tan WC, et al. Design and analytic considerations in determining the cost effectiveness of early intervention in asthma for a multinational clinical trial. Control Clin Trials 2001;22:420-37.
121. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 112:1229-36.
122. Simon GE, Katon WJ, von Korff M, Unutzer J, Lin EH, Walker EA, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001;158:1638-44.
123. Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 2001; 58:181-7.
124. Simon GE, von Korff M, Ludman E, Katon WJ, Rutter C, Unutzer J, et al. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care 2002;40:941-50.
125. Bedi N. Assessing the effectiveness of treatment of depression in primary care. Br J Psychiatry 2000; 177:312-18.
126. Peveler R, George C, Kinmonth A-L, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ 1999;319: 612-15.
127. Kirsch I, Moore TJ, Scorboria A, Nicholls SS. The Emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention and Treatment 2002; 5(23).
128. Charney D, Nemeroff C, Lewis L. National Depressive and Manic-Depressive Association Consensus Statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 2002; 59:262-70.
129. Anon. Mild depression in general practice: time for a rethink? Drug Ther Bull 2003;41:60-4.